In the latest session, X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed at $1.45 down -0.68% from its previous closing price of $1.46. In other words, the price has decreased by -$0.0100 from its previous closing price. On the day, 3065116 shares were traded. XFOR stock price reached its highest trading level at $1.6000 during the session, while it also had its lowest trading level at $1.4150.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
For a deeper understanding of X4 Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.34 and its Current Ratio is at 5.34. In the meantime, Its Debt-to-Equity ratio is 1.14 whereas as Long-Term Debt/Eq ratio is at 1.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 11 ’24 when Mostafa Adam S. sold 52,500 shares for $0.88 per share. The transaction valued at 46,347 led to the insider holds 0 shares of the business.
Ragan Paula sold 49,678 shares of XFOR for $43,856 on Mar 11 ’24. The President and CEO now owns 765,068 shares after completing the transaction at $0.88 per share. On Mar 11 ’24, another insider, DiBiase Mary, who serves as the Chief Operating Officer of the company, sold 15,409 shares for $0.88 each. As a result, the insider received 13,591 and left with 291,752 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 244.35M and an Enterprise Value of 188.41M.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.48, which has changed by 74.70% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $2.58, while it has fallen to a 52-week low of $0.57. The 50-Day Moving Average of the stock is 0.9251, while the 200-Day Moving Average is calculated to be 1.1383.
Shares Statistics:
For the past three months, XFOR has traded an average of 1.93M shares per day and 5.14M over the past ten days. A total of 167.43M shares are outstanding, with a floating share count of 121.91M. Insiders hold about 27.41% of the company’s shares, while institutions hold 35.95% stake in the company. Shares short for XFOR as of Feb 29, 2024 were 14.4M with a Short Ratio of 7.47, compared to 12.8M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.61% and a Short% of Float of 8.63%.
Earnings Estimates
There are 6 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.15 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.18, while EPS last year was -$0.16. The consensus estimate for the next quarter is -$0.01, with high estimates of $0.36 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.06 and -$0.75 for the fiscal current year, implying an average EPS of -$0.45. EPS for the following year is -$0.44, with 7 analysts recommending between -$0.07 and -$0.64.
Revenue Estimates
Based on 7 analysts’ estimates, the company’s revenue will be $60.45M in the next fiscal year. The high estimate is $163.1M and the low estimate is $4.27M. The average revenue growth estimate for next year is up 271.30% from the average revenue estimate for this year.
